Certara (NASDAQ:CERT) Issues FY24 Earnings Guidance

Certara (NASDAQ:CERT) issued an update on its FY24 earnings guidance on Tuesday morning. The company provided earnings per share guidance of $0.41 to $0.46 for the period, compared to the consensus earnings per share estimate of $0.44. The company issued revenue guidance of $385 million to $400 million, compared to the consensus revenue estimate of $391.38 million.

Certara Stock Performance

NASDAQ CERT traded down $2.05 during trading hours on Wednesday, hitting $13.03. 1,541,818 shares of the stock were exchanged, compared to its average volume of 573,008. The company has a market cap of $2.10 billion, a price-to-earnings ratio of -33.41, a price-to-earnings-growth ratio of 5.39 and a beta of 1.52. Certara has a 12-month low of $11.81 and a 12-month high of $19.87. The stock has a 50-day moving average of $15.10 and a 200 day moving average of $16.52. The company has a quick ratio of 3.26, a current ratio of 3.26 and a debt-to-equity ratio of 0.27.

Certara (NASDAQ:CERT) last posted its quarterly earnings results on Tuesday, May 7th. The company reported $0.06 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.07 by ($0.01). The firm had revenue of $96.65 million for the quarter, compared to analysts’ expectations of $94.48 million. Certara had a positive return on equity of 4.08% and a negative net margin of 17.02%. As a group, equities research analysts forecast that Certara will post 0.28 earnings per share for the current year.

Analysts Set New Price Targets

CERT has been the subject of several analyst reports. Barclays cut their price target on shares of Certara from $18.00 to $16.00 and set an equal weight rating for the company in a report on Friday, June 28th. KeyCorp cut their price target on shares of Certara from $23.00 to $20.00 and set an overweight rating for the company in a report on Thursday, July 11th. Robert W. Baird lowered their target price on shares of Certara from $19.00 to $18.00 and set a neutral rating on the stock in a research report on Wednesday. JMP Securities restated a market perform rating on shares of Certara in a research report on Wednesday, July 10th. Finally, UBS Group lowered their target price on shares of Certara from $20.00 to $16.00 and set a neutral rating on the stock in a research report on Wednesday. Eight research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of Hold and a consensus target price of $18.83.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.